Physician profile
Marcus Carty
NPI 1952755696
$562.48
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $15.55 · 2021: $101 · 2022: $146 · 2023: $66.40 · 2024: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $299.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $108.27 | 2022-2023 | Rybelsus, Ozempic |
| Abbvie INC. | $98.54 | 2021-2024 | |
| Pfizer INC. | $77.28 | 2024 | |
| Exact Sciences Corporation | $71.11 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $35.26 | 2020-2021 | |
| Amgen INC. | $28.01 | 2024 | Evenity, Prolia |
| E.R. Squibb & Sons, L.L.C. | $26.86 | 2024 | Eliquis |
| Regeneron Healthcare Solutions, INC. | $22.51 | 2024 | Dupixent |
| Hologic Sales and Service, LLC | $21.40 | 2023 | Aptima, Thinprep 2000 Processor |
| Boston Scientific Corporation | $19.00 | 2021 | |
| Optinose US, INC. | $17.10 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.80 | 2022 | |
| Idorsia Pharmaceuticals US INC | $12.33 | 2022 | |
| Upsher-Smith Laboratories LLC | $12.01 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Carty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.